Solutions
keyboard_arrow_downServices
keyboard_arrow_downSupport & Resources
keyboard_arrow_downCompany
keyboard_arrow_downContact
Soluble RAGE (sRAGE), a circulating form of the Advanced Glycation End Products receptor, offers an exciting biomarker opportunity for early detection, risk assessment, and disease monitoring.
Get in touch to discover more
To find out more about the Novel Biomarkers – sRAGE, enquire now.
sRAGE
sRAGE is the soluble form of the RAGE receptor found in blood. Unlike membrane-bound RAGE, sRAGE lacks a signalling domain, meaning it does not trigger inflammation. Instead, it acts as a "decoy receptor", binding harmful ligands and inhibiting pro-inflammatory RAGE signalling.
This anti-inflammatory potential makes sRAGE an important marker of immune balance and a candidate for identifying individuals at risk of developing chronic disease.
Other Applications
sRAGE demonstrates promising potential for broader clinical applications, including risk assessment, early diagnosis, and treatment monitoring in conditions such as obesity, diabetes, liver disease, cardiovascular disease, and chronic kidney disease.
Biochip Array Technology
Randox biochip technology enables precise measurement of sPD-1, providing valuable insights into immune regulation and disease progression.
The Evidence MultiSTAT
Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
MultiSTAT Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.